AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12088960 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Matcher
Number of subjects: 223
Study 12088960 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Number of subjects: 223
Study 12088960 — intervention group
Group type: COMPARATOR
Intervention: Electro‐acupuncture
Number of subjects: 223
Study 12088960 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil (fast‐acting opiate)
Number of subjects: 223
Study 10500938 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 56
Study 10500938 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal Tube (ETT)
Number of subjects: 56
Study 10500938 — intervention group
Group type: COMPARATOR
Intervention: Both groups (LMA and ETT)
Number of subjects: 56
Study 8759495 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreoscan
Number of subjects: 18
Study 8759495 — intervention group
Group type: EXPERIMENTAL
Intervention: MIBG
Number of subjects: 18
Study 8759495 — intervention group
Group type: EXPERIMENTAL
Intervention: I131-MIBG
Number of subjects: 18
Study 1746997 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretics
Number of subjects: 176
Study 1746997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 6181331 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard amitriptyline (75 mg)
Number of subjects: 8
Study 6181331 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release amitriptyline (75 mg)
Number of subjects: 8
Study 6181331 — intervention group
Group type: COMPARATOR
Intervention: Standard amitriptyline
Number of subjects: 8
Study 6181331 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release amitriptyline
Number of subjects: 8
Study 31535806 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin plus Androgel 1% topically
Number of subjects: 60
Study 31535806 — intervention group
Group type: COMPARATOR
Intervention: Silodosin (monotherapy)
Number of subjects: 60
Study 30501871 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 300 mg/m2 continuously from day 15 of induction during chemotherapy
Number of subjects: 155
Study 30501871 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment
Number of subjects: 155
Study 26656144 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 858
Study 26656144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 858
Study 26656144 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up sST2 levels
Number of subjects: 858
Study 26656144 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline sST2 levels
Number of subjects: 858
Study 26656144 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistently high sST2 levels (>60 ng/ml) at follow-up
Number of subjects: 858
Study 26656144 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and follow-up sST2 levels
Number of subjects: 858
Study 24288691 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal EGD (UT group)
Number of subjects: 165
Study 24288691 — intervention group
Group type: COMPARATOR
Intervention: Standard endoscope (SO group)
Number of subjects: 165
Study 24288691 — intervention group
Group type: COMPARATOR
Intervention: Thin endoscope (UO group)
Number of subjects: 165
Study 23017309 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (4 capsules daily for 8 weeks, each containing 180 mg eicosapentaenoic acid and 120 mg docosahexanoic acid)
Number of subjects: 64
Study 23017309 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 64
Study 23017309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 20816912 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg of caffeine
Number of subjects: 59
Study 20816912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 17620054 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.014 mg/d transdermal estradiol patch
Number of subjects: 382
Study 15161389 — intervention group
Group type: EXPERIMENTAL
Intervention: Singleton (square frame) inserted between targets during rapid serial visual presentation
Number of subjects: 0
Study 15161389 — intervention group
Group type: EXPERIMENTAL
Intervention: Singleton containing the key target feature
Number of subjects: 0
Study 15161389 — intervention group
Group type: EXPERIMENTAL
Intervention: Singleton not possessing the key target feature
Number of subjects: 0
Study 11673342 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ghrelin in CHF patients with cachexia (n=28)
Number of subjects: 74
Study 11673342 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ghrelin in CHF patients without cachexia (n=46)
Number of subjects: 74
Study 11673342 — intervention group
Group type: COMPARATOR
Intervention: Plasma ghrelin in all CHF patients (n=74)
Number of subjects: 74
Study 11673342 — intervention group
Group type: COMPARATOR
Intervention: Plasma ghrelin in control subjects (n=12)
Number of subjects: 74
Study 11673342 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating GH in CHF patients with cachexia
Number of subjects: 74
Study 11673342 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating TNF-alpha in CHF patients with cachexia
Number of subjects: 74
Study 11673342 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of plasma ghrelin with GH
Number of subjects: 74
Study 11673342 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of plasma ghrelin with TNF-alpha
Number of subjects: 74
Study 11673342 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of plasma ghrelin with body mass index
Number of subjects: 74
Study 9849454 — intervention group
Group type: EXPERIMENTAL
Intervention: IVA (ifosfamide, vincristine and actinomycin D) for patients with completely resected primary tumour (3 courses)
Number of subjects: 186
Study 9849454 — intervention group
Group type: EXPERIMENTAL
Intervention: IVA (ifosfamide, vincristine and actinomycin D) for patients with incompletely resected tumour (6 to 10 courses)
Number of subjects: 186
Study 9849454 — intervention group
Group type: EXPERIMENTAL
Intervention: Local therapy (surgery +/- radiotherapy) for patients remaining in partial remission
Number of subjects: 186
Study 9849454 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited surgery followed by three courses of IVA
Number of subjects: 186
Study 9849454 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (after initial biopsy)
Number of subjects: 186
Study 9849454 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus conservative local treatment (limited surgery or radiotherapy for residual disease)
Number of subjects: 186
Study 9849454 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive local therapy (radical wide field radiotherapy or radical surgery or both)
Number of subjects: 186
Study 7926134 — intervention group
Group type: EXPERIMENTAL
Intervention: KTP/532 laser laparoscopy (neosalpingostomy)
Number of subjects: 113
Study 7926134 — intervention group
Group type: EXPERIMENTAL
Intervention: KTP/532 laser laparoscopy (salpingostomy)
Number of subjects: 113
Study 7926134 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral neosalpingostomy
Number of subjects: 113
Study 7926134 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral salpingostomy
Number of subjects: 113
Study 7926134 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with endometriosis
Number of subjects: 113
Study 7926134 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without endometriosis but with other infertility factors
Number of subjects: 113
Study 7926134 — intervention group
Group type: EXPERIMENTAL
Intervention: Ectopic pregnancies
Number of subjects: 113
Study 2808258 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (double-blind trial)
Number of subjects: 79
Study 2808258 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group without ANX)
Number of subjects: 79
Study 798586 — intervention group
Group type: EXPERIMENTAL
Intervention: ifosfamide (Holoxan) administered as massive-dose treatment, daily dosage of 50 to 60 mg/kg on 5 consecutive days
Number of subjects: 390
Study 798586 — intervention group
Group type: COMPARATOR
Intervention: ifosfamide (Holoxan)
Number of subjects: 390
Study 30940132 — intervention group
Group type: EXPERIMENTAL
Intervention: MOVIE intervention plus standard of care (SoC) provided by mentor-mothers (community health workers)
Number of subjects: 1008
Study 30940132 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) provided by mentor-mothers (community health workers)
Number of subjects: 1008
Study 30940132 — intervention group
Group type: EXPERIMENTAL
Intervention: MOVIE intervention plus standard of care (SoC)
Number of subjects: 1008
Study 30940132 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 1008
Study 29077146 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group (45 patients)
Number of subjects: 137
Study 29077146 — intervention group
Group type: COMPARATOR
Intervention: Conventional rosuvastatin dose group (45 patients, 10 mg/d)
Number of subjects: 137
Study 29077146 — intervention group
Group type: EXPERIMENTAL
Intervention: Large rosuvastatin dose group (47 patients, 20 mg/d)
Number of subjects: 137
Study 26243579 — intervention group
Group type: EXPERIMENTAL
Intervention: Final kissing inflation (FKI)
Number of subjects: 514
Study 26243579 — intervention group
Group type: COMPARATOR
Intervention: Leave-alone strategy
Number of subjects: 514
Study 26243579 — intervention group
Group type: COMPARATOR
Intervention: Crush technique
Number of subjects: 514
Study 23847491 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 55
Study 23847491 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 21663427 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment for 8-12 weeks
Number of subjects: 67
Study 21663427 — intervention group
Group type: COMPARATOR
Intervention: Control group without medication
Number of subjects: 67
Study 19223284 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg once daily
Number of subjects: 23504
Study 19223284 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg once daily
Number of subjects: 23504
Study 19223284 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg OA cohort
Number of subjects: 23504
Study 19223284 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg OA cohort
Number of subjects: 23504
Study 19223284 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib RA cohort
Number of subjects: 23504
Study 19223284 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75 mg twice daily
Number of subjects: 23504
Study 16510058 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 0
Study 16510058 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multidisciplinary programs
Number of subjects: 0
Study 16510058 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapies
Number of subjects: 0
Study 15120553 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning of new names
Number of subjects: 5
Study 15120553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical learning effect
Number of subjects: 5
Study 11739476 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ghrelin (5.0 pmol/kg/min)
Number of subjects: 9
Study 11739476 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 9
Study 9351694 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 weeks of training involving both continuous and interval ergocycle exercise sessions
Number of subjects: 36
Study 9351694 — intervention group
Group type: COMPARATOR
Intervention: Control group (13 subjects: 5 women and 8 men)
Number of subjects: 36
Study 8243076 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear 'black box' NARMAX identification package
Number of subjects: 0
Study 8243076 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured two‐compartment Belville model
Number of subjects: 0
Study 8243076 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 0
Study 8243076 — intervention group
Group type: COMPARATOR
Intervention: Controlled gas mixture
Number of subjects: 0
Study 2435738 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial prostacyclin infusion
Number of subjects: 29
Study 2435738 — intervention group
Group type: COMPARATOR
Intervention: Praxilene (naftidrofuryl oxalate)
Number of subjects: 29
Study 29644962 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (400 mg/kg)
Number of subjects: 540
Study 28314746 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-level hygiene education program and water quality intervention using riverbank filtration technology
Number of subjects: 0
Study 28314746 — intervention group
Group type: EXPERIMENTAL
Intervention: Riverbank filtration-treated water
Number of subjects: 0
Study 25212409 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (30 mg oral)
Number of subjects: 24
Study 25212409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 22134736 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous closed-suction drainage
Number of subjects: 105
Study 22134736 — intervention group
Group type: COMPARATOR
Intervention: Conventional closed-suction drainage
Number of subjects: 105
Study 21226544 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention for six weeks
Number of subjects: 209
Study 21226544 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 209
Study 18505083 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care plus MLT (20 mg/day, orally in the evening)
Number of subjects: 846
Study 18505083 — intervention group
Group type: EXPERIMENTAL
Intervention: MLT plus SC low-dose IL-2 (3 MIU/day for 5 days/week, for 4 consecutive weeks)
Number of subjects: 846
Study 18505083 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care only
Number of subjects: 846
Study 17179687 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder Training (BT)
Number of subjects: 139
Study 17179687 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine (To, 2 mg twice daily)
Number of subjects: 139
Study 17179687 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Bladder Training and Tolterodine (Co)
Number of subjects: 139
Study 17179687 — intervention group
Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 139
Study 15249259 — intervention group
Group type: EXPERIMENTAL
Intervention: Group‐mediated cognitive behavioral physical activity intervention program (GMCB)
Number of subjects: 147
Study 15249259 — intervention group
Group type: COMPARATOR
Intervention: Traditional cardiac rehabilitation program (CRP)
Number of subjects: 147
Study 11423457 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification (Phako)
Number of subjects: 476
Study 11423457 — intervention group
Group type: COMPARATOR
Intervention: Extracapsular cataract extraction (ECCE)
Number of subjects: 476
Study 9257199 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspired oxygen concentration (FIO2) decreased from 21% to 10%
Number of subjects: 16
Study 9257199 — intervention group
Group type: EXPERIMENTAL
Intervention: FIO2 levels reduced to ranges of 95% to 90%, 89% to 85%, 84% to 80%, and 79% to 70%
Number of subjects: 16
Study 8324274 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% podophyllotoxin solution
Number of subjects: 60
Study 8324274 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% podophyllotoxin cream
Number of subjects: 60
Study 8324274 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% podophyllotoxin cream
Number of subjects: 60
Study 8324274 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 3706190 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day of pyridoxine X HCl
Number of subjects: 12
Study 3706190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 27863185 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 271
Study 27863185 — intervention group
Group type: COMPARATOR
Intervention: Best practice care
Number of subjects: 271
Study 26722670 — intervention group
Group type: EXPERIMENTAL
Intervention: Total urinary phthalate metabolites (free plus glucuronidated forms)
Number of subjects: 293
Study 26722670 — intervention group
Group type: EXPERIMENTAL
Intervention: Free mono‐butyl phthalate (MBP)
Number of subjects: 293
Study 26722670 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mono‐butyl phthalate (MBP)
Number of subjects: 293
Study 26722670 — intervention group
Group type: EXPERIMENTAL
Intervention: Free mono‐(2‐ethyl‐5‐carboxypentyl) phthalate (MECPP)
Number of subjects: 293
Study 26722670 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mono‐(2‐ethyl‐5‐carboxypentyl) phthalate (MECPP)
Number of subjects: 293
Study 26722670 — intervention group
Group type: EXPERIMENTAL
Intervention: Mono‐ethyl phthalate (MEP)
Number of subjects: 293
Study 26722670 — intervention group
Group type: EXPERIMENTAL
Intervention: Mono‐(2‐ethyl‐5‐oxohexyl) phthalate (MEOHP)
Number of subjects: 293
Study 24419825 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional brace for 3 weeks
Number of subjects: 186
Study 24419825 — intervention group
Group type: COMPARATOR
Intervention: Walking boot with weight‐bearing allowed, pain management, ice, and elevation with restricted joint mobilization for 3 weeks
Number of subjects: 186
Study 22803768 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly oral ibandronate 150 mg
Number of subjects: 140
Study 22803768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 20382081 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 226
Study 20382081 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 226
Study 18535879 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium‐99m methoxyisobutylisonitrile (Tc‐99m MIBI) gated SPECT
Number of subjects: 23
Study 18535879 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls, 20 patients total, 12 men and 8 women)
Number of subjects: 23
Study 11464714 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients after stroke
Number of subjects: 56
Study 11464714 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 56
Study 9500801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid
Number of subjects: 20
Study 9500801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid/glucose mixture
Number of subjects: 20
Study 9500801 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20
Study 9500801 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 20
Study 7875147 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF (60 micrograms/m2) with antibiotics (ticarcillin‐clavulanate plus netilmicin)
Number of subjects: 91
Study 7875147 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF with amphotericin B
Number of subjects: 91
Study 3277154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 47
Study 3277154 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin
Number of subjects: 47
Study 30711184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketorolac (31.5 mg)
Number of subjects: 70
Study 30711184 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (1000 mg) and Ibuprofen (600 mg)
Number of subjects: 70
Study 29125435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention aimed at promoting CRC screening
Number of subjects: 416
Study 29125435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociodemographic and psychosocial variables
Number of subjects: 416
Study 25647447 — intervention group
Group type: EXPERIMENTAL
Intervention: Network Support (NS)
Number of subjects: 210
Study 25647447 — intervention group
Group type: EXPERIMENTAL
Intervention: Network Support+Contingency Management (NS+CM)
Number of subjects: 210
Study 25647447 — intervention group
Group type: COMPARATOR
Intervention: Case Management (CaseM)
Number of subjects: 210
Study 22753402 — intervention group
Group type: EXPERIMENTAL
Intervention: FIN-RACo + Infliximab (INFL)
Number of subjects: 99
Study 22753402 — intervention group
Group type: COMPARATOR
Intervention: FIN-RACo + Placebo (Pla)
Number of subjects: 99
Study 21640958 — intervention group
Group type: EXPERIMENTAL
Intervention: Melody cues for titles
Number of subjects: 0
Study 21640958 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyrics as a source of familiarity
Number of subjects: 0
Study 21640958 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of familiarity
Number of subjects: 0
Study 18287441 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated CO2 insufflation
Number of subjects: 74
Study 16497281 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral precue (140 ms) indicating the signal location with 80% validity.
Number of subjects: 2
Study 16497281 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification images technique used to estimate perceptual templates.
Number of subjects: 2
Study 12889783 — intervention group
Group type: COMPARATOR
Intervention: 500‐mg clarithromycin tablet (Test formulation)
Number of subjects: 24
Study 12889783 — intervention group
Group type: COMPARATOR
Intervention: 500‐mg clarithromycin tablet (Reference formulation)
Number of subjects: 24
Study 10861653 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 0
Study 9378847 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg every 12 hours
Number of subjects: 16
Study 9378847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8466017 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle massage of the epigastric area for 30 min
Number of subjects: 16
Study 8466017 — intervention group
Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 16
Study 31725787 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy
Number of subjects: 3300
Study 30056104 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher AHEI-2010 cumulative average score (reflecting long-term healthy diet quality)
Number of subjects: 459